CSI Market
Sign In | Register

Acrivon Therapeutics Inc (ACRV) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access ACRV Annual Cash Flow →
Cash flow performance over multiple periods helps investors evaluate the stability of Acrivon Therapeutics Inc's cash-generating activities.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-37.01
Depreciation & amortization0.79
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation4.40
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Non Cash Lease Expense-
Anti Dilution Right Assumed With License Agreement-
Change In Fair Value Of Preferred Stock Tranche Rights-
Change In Fair Value Of Anti Dilution Right-
Gain Loss Upon Extinguishment Of P P P Loan-
Increase Decrease In Accrued Expenses And Other Liabilities-
Increase Decrease In Accrued Expense And Other Liabilities-
Increase Decrease In Accrued Expense And Other Current Liabilities-3.38
Non Cash Operating Lease Expense0.27
Income taxes0.00
Losses/ -gains on Investments net0.00
Accounts Receivable0.00
Increase (Decrease) in Accounts Payable-1.42
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-0.33
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net-0.22
Payments for (Proceeds from) Other Operating Activities-1.61
Discontinued operations0.00
Net Cash flow from Operating Activities-35.40
Investing Activities
Capital Expenditures-0.10
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Available-for-sale Securities55.00
Payments to Acquire Available-for-sale Securities, Debt-26.83
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities28.07
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock7.30
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net-0.07
Other net0.00
Payments Of Deferred Offering Cost-
Right Of Use Asset Obtained In Exchange For Operating Lease Liability-
Deferred Offering Costs In Accounts Payable And Accrued Expenses-
Available For Sale Debt Securities Gross Unrealized Loss-
Proceeds From Issuance Of Series B Preferred Stock Net Of Issuance Costs And Settlement Of Anti Dilution Right-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations41.70
Purchases Of Property And Equipment Included In Accounts Payable And Accrued Expenses-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities7.24
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-35.50
Total Cash Flow-0.09
4 historic quarters locked

Sign in to unlock the full Acrivon Therapeutics Inc cash flow history.

Sign In Create Free Account

About Acrivon Therapeutics Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-346819

Figures are derived from filed reports and may be restated. Historical data is subject to revision.